548 Introduction: The trastuzumab (MW 141kDa) is monoclonal antibody against HER2
receptor protien. We demonstrated the feasibility of Ga-68 Trastuzumab Fab (45kDa) for …

Breast cancer is the most common cause of mortality among women worldwide. Among all
subtypes, HER2-positive breast cancers are highly aggressive and have poor prognosis …

Methods Fab has been generated by papain digestion and conjugated with the bifunctional
chelating agent NOTA. The SDS-PAGE and MALDI-TOF were used to see the integrity of …

Background Inherited genes, hormonal imbalance, environmental factors, and mutation in
genes are responsible for the development of breast cancer in females. Nowadays, passive …

Purpose Affibody molecules represent a novel class of high-affinity agents for radionuclide
tumour targeting. Fusion of the Affibody molecules with an albumin-binding domain (ABD) …

932 Objectives: Monoclonal antibodies (mAbs) have become broadly used for treatment of
cancer because they can be engineered to bind specifically to the target and therefore …

Targeting HER 2 for imaging and therapy in nuclear medicine has been used with a special
emphasis on developing more powerful radiopharmaceuticals. Zirconium-89 plays an …

Purpose Molecular imaging of tumor HER2 expression may allow patient selection for HER2-
targeted therapies. Our aim was to introduce hexahistidine (His 6) peptides into pertuzumab …

INTRODUCTION: The human epidermal growth factor receptor-2 (HER2) gene is amplified
in 25% of invasive breast cancers, and receptor overexpression has been noted in up to …

The oncogene HER2 is an important molecular target in oncology because it is associated
with aggressive disease and the worst prognosis. The development of non-invasive imaging …